Evidence has shown that APOE-ε4 carriers have an increased risk for AD, with heterozygous carriers of one ε4 allele being 3-4 times more likely to develop this neurodegenerative disorder than non-carriers, and with the risk for homozygous carriers being even higher (4). Here, APOE is linked to Alzheimer disease.